Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe.

The aims of this study were to determine the frequency of dialysis and kidney transplantation and to estimate the regularity of comprehensive conservative management (CCM) for patients with kidney failure in Europe. This study uses data from the ERA-EDTA Registry. Additionally, our study included supplemental data from Armenia, Germany, Hungary, Ireland, Kosovo, Luxembourg, Malta, Moldova, Montenegro, Slovenia and additional data from Israel, Italy, Slovakia using other information sources. Through an online survey, responding nephrologists estimated the frequency of CCM (i.e. planned holistic care instead of kidney replacement therapy) in 33 countries. In 2016, the overall incidence of replacement therapy for kidney failure was 132 per million population (pmp), varying from 29 (Ukraine) to 251 pmp (Greece). On 31 December 2016, the overall prevalence of kidney replacement therapy was 985 pmp, ranging from 188 (Ukraine) to 1906 pmp (Portugal). The prevalence of peritoneal dialysis (114 pmp) and home hemodialysis (28 pmp) was highest in Cyprus and Denmark respectively. The kidney transplantation rate was nearly zero in some countries and highest in Spain (64 pmp). In 28 countries with five or more responding nephrologists, the median percentage of candidates for kidney replacement therapy who were offered CCM in 2018 varied between none (Slovakia and Slovenia) and 20% (Finland) whereas the median prevalence of CCM varied between none (Slovenia) and 15% (Hungary). Thus, the substantial differences across Europe in the frequency of kidney replacement therapy and CCM indicate the need for improvement in access to various treatment options for patients with kidney failure.

A transitory polycytaemia after parathyroidectomy for secondary hyperparathyroidism--a literature survey and a case study.

The present study is a literature review of a nephrological problem--secondary hyperparathyroidism, its surgical treatment and the effect of the intervention on the anemic syndrome in patients with chronic renal failure (CRF) on hemodialysis treatment. We present a case of a 29-year-old female hemodialysis patient with a transitory polycytaemia (duration of 5 months) after parathyroidectomy for secondary hyperparathyroidism. Prior to surgery she was constantly anemic in spite of epoetin treatment lasting 10 years. Ten days after the parathyroidectomy there was a crucial decline of parathormone (from 900.4 pg/ ml to 21.4 pg/ml) and ionized calcium (iCa) (from 1.23 mmol/l to 0.79 mmol/l) and the hemoglobin level reached 170 g/l with a hematocrit of 0.53. After discontinuation of epoetin treatment (58.8 U/kg/week) in the following 5 months hemoglobin level declined reaching 144 g/l. Two years after parathyroidectomy the patient is still with normal hemoglobin level (125-135 g/l) without epoetin treatment. We discuss the likely mechanisms for the early onset of polycytaemia after parathyroidectomy as well as the importance of adequate control of secondary hyperparathyroidism in the management of anemia in chronic renal insufficiency.

First impressions of cardiovascular calcification treatment in hemodialysis patients with a new dialysis fluid containing sodium thiosulphate (STS).

BACKGROUND: Cardiovascular calcification (CVC) in hemodialysis patients (HDP) causes cardiovascular pathology. Up until now very few drugs and therapeutic interventions have been able to reduce cardiovascular calcium deposits in hemodialysis patients and the process requires more than a year. Our idea in this study was to test 2 calcium binders--sodium thiosulfate (STS) and dinatrium ethylene diamine tetraacetic acid (DNEDTA)--for prevention and treatment of cardiovascular calcification of hemodialysis patients, using both substances not as an intravenous infusion but by adding them to the liquid bicarbonate part of the dialysis fluid. MATERIAL AND METHODS: 6 HDPs were treated with sodium thiosulphate (STS), 6 with dinatrium ethylene diamine tetraacetic acid (DNEDTA), and 6 patients served as controls. Electrolytes, liver function, markers of inflammation, oxidative stress, bone metabolism, spiral computed tomography (SCT) of coronary CVC and bone densitometry were performed twice (start and end of the study). RESULTS: Starting blood parameters were similar to the end (STS group). No toxic or side effects from STS were observed. Initially in the DNEDTA group all the patients had vomiting so we excluded DNEDTA from the study. SCT found a significant reduction of calcification in 4 patients (STS group) and retardation in 2 patients comparatively to controls. CONCLUSIONS: The first results are hopeful, but the number of the patients was small, so we are enlarging the enrollment in the expectation of corroborating our results soon.